Related Experiment Videos
Phospholamban as a therapeutic modality in heart failure
Guoxiang Chu1, Evangelia G Kranias
1Department of Internal Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0575, USA.
Novartis Foundation Symposium
|October 6, 2006
Summary
Phospholamban (PLN) dysfunction impairs heart function by inhibiting SERCA2. Modulating PLN activity and phosphorylation shows promise for treating heart failure and dilated cardiomyopathy.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Heart failure is associated with increased diastolic calcium and impaired relaxation, linked to sarcoplasmic reticulum Ca-ATPase (SERCA2) dysfunction.
- Phospholamban (PLN) regulates SERCA2 activity and cardiac contractility, acting as a reversible inhibitor.
- Altered PLN levels and phosphorylation are critical for cardiac calcium handling and contractility, particularly in heart failure.
Purpose of the Study:
- To investigate the role of phospholamban (PLN) in regulating SERCA2 function and cardiac contractility.
- To explore the implications of PLN modulation as a therapeutic strategy for heart failure.
Main Methods:
- Studies in genetically altered mouse models to assess PLN levels and phosphorylation.
- Investigation of PLN ablation and phosphatase inhibition in experimental heart failure models.
- Analysis of human PLN mutations linked to dilated cardiomyopathy.
Main Results:
- Depressed cardiac contractility in heart failure is linked to increased PLN/SERCA2 ratios and decreased PLN phosphorylation.
- PLN ablation successfully rescued cardiac remodeling and dysfunction in mouse models.
- Inhibition of phosphatase activity restored contractile parameters in failing rat hearts.
- Human PLN mutations associated with altered PLN dephosphorylation are linked to dilated cardiomyopathy.
Conclusions:
- Phospholamban (PLN) plays a critical role in regulating cardiac function and is implicated in heart failure and dilated cardiomyopathy.
- Modulating PLN activity and phosphorylation represents a potential therapeutic target for heart failure.
- Further research in higher mammals is warranted to explore PLN's therapeutic potential.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...